afternoon, thank fiscal for the Thank you. Good you reported results. us. close After and second everyone, joining Forian quarter XXXX today,
success second in long-term executing our quarter strategy. reflect results against Our
that I call, As stated are of has able health now last strategically the a to as enterprise care operating environment. macroeconomic we a headwinds navigate focused been challenging
of breakeven year-over-year quarter reached with revenue schedule. adjusted organic and strong results Forian operational XX% delivered growth EBITDA another ahead of
examples second are I'll will provide to some how Today, used, a details speak financial solutions the couple results. share highlights and then of of and our from Mike quarter on our
financial operational Forian In strong the results. second quarter, and delivered
represents quarter $X.X second totaled Forian's noted, as million, year-over-year revenue which, growth. XX% was
breakeven team's Our previous net and continuing loss $XXX,XXX, of adjusted on growth plan as these proud was our the despite positive the for I’m from and improvement quarters. EBITDA delivering quarter we reflecting challenging from EBITDA hitting operations milestone macroeconomic and the continued $X.X consistent work environment. results our adjusted solid million, in a was executed
As some discretionary sales previously saw and spending the still first and budgets we reported, pending cycles. in longer quarter,
life our to by and has expertise Forian's care health customers. high-value science growth been fueled solutions delivering information our in
development to analytics their leveraging data few commercial our examples Chronos to lake power data and clinical post-launch to ranging share market-leading are Our assets Chronos trial of customers real-world improve a evidence. I'll execution performance. solutions business how from in our
surveillance quantify and information and supports market test identify optimal studies. select use size Given sites life X protocol all protocol and to CROs need trial the of drug optimized extraordinary feasibility, market, bringing post-market device cost cases. of trial FDA-approved opportunity a design, and manufacturers Chronos to actual or these conduct science Phase
of Upon and launch, provider Life consumers of measurement each on marketing science insights to health and including year and physicians, innovative billions Forian approval targeting dollars delivers spend and pricing and companies optimization, plans. share tens that market commercial market marketing to analytic market authorization including therapeutics. patients' precertification sizing drug analytics, assessments segmentation and access prior and impact access and assessments solutions, requirements of
efficacy In health million in patient and such compliance U.S. and on and maps persistence to care terms use, Chronos in therapy of product sites health the patient care on real-world and journeys as research. and longitudinal covering XXX evidence, over patients service de-identified drug economics outcomes safety,
how products development, upon expanding life essential whom and of in companies or real-world. by which indications, their for usage and used the being for in effect. Real-world the science to hypotheses drug what is new development safety to their value efficacy, testing evidence foundation improving are new product service a the of understand is It
leakage service Chronos science to to in valuable networks, patient to In payers companies, delivers insights providers facilities and developing understanding of use to high-value referring systems addition health care steer the across of provider the systems competitor health to life quantifying tracking providers and efficient, high-quality patients delivery their and interested dynamics care.
our Our of health understanding data. care deep customers appreciate
Our and deliver to high-value innovative develop continue products Chronos. engineers solution from
Increasingly, insight so, are customers artificial greater intelligence their Chronos. are customers addition, on products, our we and their trained the the changing marketplace. of In into doing customers markets By gaining AI growing attention leverage are a to rapidly to care. solutions dynamics generative our beginning health enabling
to outcomes. care clients of and suited we in be improved new more empower the that there therapeutics the covering training As uniquely solutions unique improve system, data for advanced continues, health development patient AI AI delivery the models on more will believe support specific with insights momentum opportunities
improve to our sheet. continue balance we Finally,
held Forian the a of which equity interest Forian as in its consideration quarter, customer of the all in of proceeds a after end an reported, equity was cash As And we received interest million acquired. $X.X the of customer. approximately of in result,
proceeds are put for to up if $X.X and aggregate conditions of additional Forian earn-out strong amount position. million cash and improvements XXXX a and approximately may certain XXXX receive operational additional in The payments in an met.
solid acquisitions. We for intend along delivered event corporate net Overall, Forian the including use EBITDA to possible reaching purposes, financial quarter, deleveraging the general another breakeven. financial with or expansion, and milestone of business operating and proceeds adjusted the
growth, we at revenue high and margins resulted forward a to further executing look come. and cash level, flow in a to team from improved committed Our growth quarters
hand now to will go it to more our in Mike results I over detail. financial Mike? over
